News Hub | News Direct

All Industries


Article thumbnail News Release

A Liberian Gold Rush? Introducing Pasofino Gold's (TSX-V: VEIN) Dugbe Gold Project

Benzinga

By Faith Ashmore, Benzinga Pasofino Gold’s (TSX-V: VEIN) Dugbe Gold Project is in Liberia, which could be West Africa's last untapped gold exploration frontier. The Dugbe Gold Project is located in southern Liberia and is situated within a Birimian geological province. Pasofino Gold reports that the Birimian province is recognized for hosting the majority of the large and economic West African gold deposits, and the Dugbe Gold Project landholding consists of 2559 kms2 which remains largely unexplored. Further, the company is reportedly well situated in the country with the project area conveniently positioned only 70 kilometers away from the Greenville deep-water port. Through its subsidiary ARX Resources Limited, Pasofino currently owns 100% of the Dugbe Gold Project before the Government of Liberia's 10% carried interest. The project's mining rights and terms are secured by a mineral development agreement awarded by the Government of Liberia, lasting for 25 years and thereafter renewable. Although less than 10% of the project has been explored so far, Pasofino reports that the known discoveries are already promising. The Dugbe F and Tuzon areas hold a combined Measured and Indicated Resource of approximately 3.3 million ounces of gold. Multiple drill-ready targets also display abundant gold mineralization at the surface, according to Pasofino. The Bukon Jedeh area has a history of artisanal gold production spanning over 80 years and is believed to have yielded hundreds of thousands of ounces of gold. Exploration of this target by Pasofino has recently commenced. Another prospective target is the Tuzon Sackor trend, which exhibits surface gold mineralization up to a grade of 3 grams per tonne and has yet to be drilled. Pasofino is optimistic that these combined areas will lead to a further update on the company’s Resources and Reserves profile. The company believes the remaining 90% of the project area also holds immense potential for further discoveries. The project holds a large mineral reserve that supports an average annual gold production of approximately 173,000 ounces from open-pit mining. Within the mineral reserves, there is an estimated 2.76 million ounces of gold with a fully diluted mined head grade of 1.30 grams per tonne. These reserves are projected to sustain a 14-year Life of Mine (LOM). Additionally, the average annual production for the first five years is anticipated to be 200,000 ounces. The project remains scalable, according to the company. The project's strip ratio, comparing waste material to the amount of ore, is low at 4.2:1 and even lower during the initial five years of production. To support operations, a 5 million tonnes per annum (Mtpa) processing plant is planned to be built at a location conveniently situated between the two major deposits. In January 2024, Pasofino closed a non-brokered private placement of $2.3 million to insiders to fund the Dugbe Gold project which allowed the company to progress the development of the Project and the maximization of its value. Currently, a new drill program is underway to extend the Tuzon mineralization along with possible additional exploration targets previously identified. Additionally, a number of opportunities have been identified to optimize the Feasibility Study which was completed during COVID with challenges incurred during that time. Pasofino Gold is expanding its presence in the gold market at a critical time. Many anticipated that by the end of 2024, the gold rate could exceed $2,300 /oz, which would break the all-time high that was hit in March 2024. At the writing of this article in April 2024, this record has already been broken, with the gold price going above $2,400/oz. Some projections indicate that the price of gold will continue to climb in the period between 2024 and 2030 and in the most optimistic scenarios, experts believe the rate could even reach levels above $4,000 by 2030. Pasofino Gold’s Dugbe Gold project could be a critical supplier as gold prices continue to rise. Comparable project valuations within the African environment have had market cap values ranging from $200M to $600M, like Osino Twin Hills Project (TSX: OSI) and Tietto Minerals Abijar Project (ASX: TIE). At a current market cap of around $45 million, Pasofino may be one to watch. Featured photo by Peter Olexa on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 18, 2024 08:50 AM Eastern Daylight Time

Image
Article thumbnail News Release

Cordiant Digital Infrastructure targets future growth with innovative tech investments

Cordiant Digital Infrastructure Ltd

Cordiant Capital CEO and managing partner Benn Mikula provides insight into the evolving landscape of digital infrastructure, underlining the significant impact of social and technological changes. Through Cordiant Digital Infrastructure Ltd (LSE:CORD), Cordiant Capital invests in the essential components of the internet’s infrastructure, including fibre optic cabling, mobile towers, and data centres, which Mikula describes as the internet's "plumbing". These elements are integral to the transmission of data across an international network. Despite the complex and energy-intensive nature of this infrastructure, it facilitates global communication, exemplified by the potential routing of the interview through a data centre in New York. Mikula highlights several trends affecting digital infrastructure: the need for expansion due to network congestion and regulatory impacts, the installation of 5G technology requiring denser network coverage, and the surge in demand for advanced data centres driven by artificial intelligence. Cordiant Digital Infrastructure’s approach to investment is a "buy, build and grow" strategy, focusing on acquiring platforms with existing customers and expanding them, often pre-leased to reputable or governmental clients. The company successfully deployed its initial fund and plans to raise a second, targeting high-growth opportunities within digital infrastructure. Mikula also discusses innovative solutions to contemporary challenges, such as leveraging existing sites for new data centres to minimise environmental impact and investing in renewable energy sources. Looking forward, Cordiant Digital Infrastructure sees continued investment potential in towers, edge data, interconnect data centres, and backbone fibre networks, particularly in Europe and the United Kingdom, where the middle market offers attractive entry points and investment returns. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

April 18, 2024 08:48 AM Eastern Daylight Time

Video
Article thumbnail News Release

Powerhouse Energy completes key milestone for Feedstock Testing Unit with new kiln on the way

Powerhouse Energy Group PLC

Powerhouse Energy Group PLC (AIM:PHE) CEO Paul Emmitt has confirmed the completion of a significant milestone with the manufacturing of a 2.5-tonne-a-day kiln for feedstock testing by AGICO in China. Emmitt detailed the company's progress despite previous delays caused by the liquidation of the previous manufacturer. The manufacturing process was verified by SGS, an independent verification company, which confirmed the quality of work and adherence to schedule. In addition to the kiln, the development of the company’s facility includes the installation of ventilation systems and utilities, orders for a gas cleanup system from a reputed German company. Although the equipment will arrive sequentially, complicating installation, an effective installation plan is being developed, Emmitt said. Emmitt also highlighted advancements in the Feedstock Testing Unit, designed to be flexible and handle various materials for R&D purposes. Orders for this system are expected soon. The CEO expressed optimism about the feedstock testing unit being operational by the fourth quarter of the year, emphasizing the importance of safety and order in the process. Investor days are planned to allow stakeholders to visit the facility once operational. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:45 AM Eastern Daylight Time

Video
Article thumbnail News Release

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Benzinga

By Meg Flippin, Benzinga Chemotherapy and radiation are proven ways to treat cancer, but for the patients, they usually mean untold suffering. Finding effective alternatives, especially for people with rare cancers, can seem impossible. For rare cancers, there often isn’t a lot of information to help develop treatments, enough animal or cell models to test, or tumor samples to research. As a result, rare cancers account for 25 % of all cancer deaths in the U.S. Immunotherapy To Kill Cancer Cells One alternative treatment that seems to be getting attention is immunotherapy. It’s a treatment that uses the patient’s immune system to seek and kill cancer cells. Immunotherapy treatments are designed to boost a patient’s immune system so the body can work harder to destroy cancer cells. It is proving effective with companies including Citius Pharmaceuticals Inc. (NASDAQ: CTXR) advancing oncology treatments through an innovative immuno-oncology approach. Citius’ lead asset aims to leverage the body's own defense mechanisms to destroy malignant tumors. The therapy targets the interleukin-2 receptors found on malignant T-cells regulatory T-cells (Tregs), opening the potential for new therapeutic approaches to the treatment of cutaneous T-cell lymphoma (CTCL). This innovation could be transformative for individuals with rare cancers like CTCL, potentially enhancing their quality of life significantly. Additionally, Citius highlights compelling market opportunities that the company says are poised for growth. Broadly, the global cancer therapy market is forecast to grow at a CAGR of 9.12% from now until 2027, while the immuno-oncology market is projected to grow at a CAGR of 22.94%, hitting $396.07 billion by 2034. LYMPHIR Poised to Make Inroads The company’s lead immunotherapy, LYMPHIR, is under review by the U.S. Food and Drug Administration (FDA) for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. In Japan, the formulation is approved and marketed for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Just last month, the U.S. FDA accepted the resubmission of a Biologics License Application (BLA) for LYMPHIR for the treatment of patients with relapsed or refractory CTCL after at least one prior systemic therapy. According to the company, the FDA has assigned a PDUFA goal date of August 13, 2024, the company said. "We believe there remains a critical unmet need for an additional viable treatment option for patients with relapsed or refractory CTCL as current therapies are non-curative,” said Leonard Mazur, Chairman and CEO of Citius. “We are grateful for the FDA's vital support for rare disease drug development as we work to expand treatment options for patients with cutaneous T-cell lymphoma. We look forward to the FDA's decision and the potential benefit LYMPHIR may provide patients with relapsed or refractory CTCL,” continued Mazur. Citius believes the market for LYMPHIR for CTCL will exceed $400 million and is particularly attractive because it is underserved by existing treatments. The Proof Is In The Results LYMPHIR is a recombinant engineered fusion protein that combines interleukin-2 and diphtheria toxin. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. Notably, malignant T-cells and immunosuppressive regulatory T-cells share a common marker, the IL-2 receptor. Consequently, LYMPHIR targets both malignant T-cells and transiently eliminates Tregs, supporting the potential to unleash potent immune responses by the patient’s immune system against their tumors. In recent preclinical studies, denileukin diftitox has demonstrated the ability to deplete murine Tregs in-vivo and human Tregs ex vivo. In addition, the combination of denileukin diftitox with anti-PD1 showed improved tumor response and very significant improvement in survival in the combination groups relative to either therapy alone in a syngeneic mouse solid tumor model. Based on this data, two investigator-initiated trials are underway to evaluate the potential safety and efficacy of LYMPHIR in combination with Pembrolizumab (anti-PD1) in patients with recurrent or metastatic solid tumors and LYMPHIR given prior to lymphodepletion (LD) chemotherapy and CAR-T therapies for the treatment of relapsed/refractory B-cell lymphomas. The results of these preclinical trials will determine if the company will develop these treatments further. The Path To Commercialization In addition to inroads on the regularity front, the company is making strides to commercialize LYMPHIR. A spinout to form Citius Oncology is in the works. The company announced plans to form a standalone public oncology company a few months ago. In a recent press release, Citius mentioned the transaction will improve the company’s access to the public equity markets and help facilitate the commercialization of LYMPHIR. "We believe this transaction will allow us to unlock the value of LYMPHIR, and solidly position Citius Pharma to advance our diversified pipeline,” said Mazur at the time. “This transaction will enable Citius Oncology, with access to the broader capital markets, to better support the successful commercialization of LYMPHIR, if approved, and explore additional potential targeted oncology therapies. Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology.” Featured photo by the National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 18, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Europa Oil & Gas chief executive highlights entry to Equatorial Guinea in half-year results

Europa Oil & Gas (Holdings) PLC

Europa Oil & Gas (Holdings) PLC (AIM:EOG) chief executive William Holland takes Proactive's Stephen Gunnion through the company's first-half performance, highlighting its entry into Equatorial Guinea, marking its expansion into new territory with the strategic acquisition of a 42.9% interest in Antler Global, giving it a substantial stake in the EG-08 gas asset. Holland said the venture is considered a groundbreaking, drill-ready joint venture, with the potential for high success in gas exploration due to favourable geological findings similar to nearby successful fields. Further, Holland detailed the progress in assessing additional prospectivity of deeper horizons in Equatorial Guinea, with future announcements planned as the company seeks a partner for exploration drilling. Europa Oil & Gas also secured a two-year licence extension in offshore Ireland. The positive development followed extensive seismic reprocessing efforts that enhanced imaging and reduced risks associated with the project, particularly around the Inishkea West prospect. On UK operations, Holland touched on the ongoing monetization efforts for the Serenity oil discovery in the North Sea and discussed operational challenges and developments at the onshore UK sites, including the Wressle's recent downtime and upcoming drilling plans. Lastly, Holland noted the recent appointment of two new directors, enhancing the board's strategic and scientific expertise, reiterating the company's strong governance structure. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:42 AM Eastern Daylight Time

Video
Article thumbnail News Release

Hydrogen Utopia CEO discusses advances in cannabis operation and future hydrogen projects

Hydrogen Utopia International PLC

Hydrogen Utopia International PLC (LSE:HUI, OTCQB:HUIPF) CEO Aleksandra Binkowska joined Proactive's Stephen Gunnion to discuss progress at the company’s cannabis operation in Macedonia, highlighting two successful harvests and ongoing developments. Binkowska noted the company has a 49% option in Ohrid Organics, highlighting its impressive facilities and high-tech enhancements, including an advanced drying system that significantly improves product quality. Binkowska emphasized the importance of the location’s natural benefits and technological enhancements for achieving high-quality outputs. Currently, Hydrogen Utopia is awaiting laboratory results to officially confirm the product quality, which is necessary for obtaining the requisite governmental paperwork for product sales. She mentioned preparations for EU GMP certification audits, which will facilitate entry into the European market at higher certification levels, potentially allowing for a higher product price point. Furthermore, Binkowska outlined the financial success of Ohrid Organics, projecting earnings that would fund Hydrogen Utopia’s first waste plastics hydrogen facility. The profits from Ohrid could potentially finance this without additional capital raising, underscoring the strategic advantage of the investment. She also highlighted the supportive role of the Macedonian government in facilitating the company's initiatives in both the cannabis and hydrogen sectors. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:40 AM Eastern Daylight Time

Video
Article thumbnail News Release

Iofina reveals strong start to 2024 with increased iodine production

Iofina PLC

Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker takes Proactive's Stephen Gunnion through the company's first-quarter operating performance, which included a 15.5% year-over-year increase in production to 123.7 metric tonnes of crystalline iodine. This growth is attributed largely to the addition of the IO#9 plant, which commenced operations in the latter half of the previous year. Iofina operates six plants that extract iodine from brine water co-produced with oil and gas, with expectations to produce between 275 and 295 metric tonnes of iodine in the first half of the year. Becker said the company has maintained strong demand for its iodine products, holding steady prices in Huntsville through the first and entering the second quarter. He noted the company is supplying both existing and new customers, including breaking into new markets, particularly in Europe. Notably, sales of biocide derivatives used in paints and coatings have been successful. Looking ahead, Becker said Iofina is on track with the construction of IO#10, slated for the third quarter, which will further boost production. The company is also exploring potential sites for IO#11 and other future iodine extraction plants across the United States. Moreover, Iofina has renegotiated a brine supply contract, ensuring stable supply at market rates, which is expected to impact profits slightly this year but is seen as beneficial for long-term growth. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:38 AM Eastern Daylight Time

Video
Article thumbnail News Release

accesso CEO unveils massive 2023 wins and plans for more growth

Accesso Technology Group PLC

Accesso Technology Group PLC (AIM:ACSO, OTC:LOQPF) chief executive Steve Brown discussed the company's strong 2023 performance with Proactive's Stephen Gunnion. The year was marked by significant achievements including surpassing profitability targets and attaining nearly $150 million in revenue. Key developments included three strategic acquisitions aimed at expanding the company’s global footprint. These acquisitions introduced new opportunities with companies like VGS in Milan and Paradocs in Canada, enhancing Accesso's market presence. In 2023, accesso secured 28 new venues and expanded its services to 273 additional venues through these acquisitions, which also incorporated 50 ski resorts in Canada, making it the largest provider of ski technology in North America. The company's growth drivers included increased sales penetration and transaction counts across existing venues. Looking ahead, Brown highlighted accesso's focus on improving profit margins by enhancing revenue efficiency and scrutinising low-margin revenue streams. Furthermore, the company has recently made a significant entry into the Saudi Arabian market through a partnership, building on the acquisition of VGS, which has been rebranded as Accesso Horizon. Brown also discussed the launch of 'Freedom', a new platform for restaurant and retail operations, which has already seen considerable uptake. For 2024, Brown mentioned the possibility of more acquisitions, supported by a strong balance sheet and cash position. The company forecasts revenues of around $160 million with a cash EBITDA margin of 17%, anticipating another robust year. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:35 AM Eastern Daylight Time

Video
Article thumbnail News Release

Learning Technologies reports steady performance amid economic challenges

Learning Technologies Group PLC

Learning Technologies Group PLC chief executive Jonathan Satchell takes Proactive's Stephen Gunnion through the company's 2023 financial results, which reveal a slight revenue decline but rising profitability. Despite the economic challenges, the company maintained strong cash flow and increased its dividend by 5% to 1.2 pence. Satchell highlighted the resilience of the company's long-term and SaaS contracts, which helped sustain performance amidst reduced corporate spending on employee development. Operational achievements included retaining all client contracts above $10 million. The company saw some revenue declines due to reduced discretionary spending but reported growth in US government contracts and expansions in Latin America and the Middle East. Another highlight was GP Strategies, which has more than doubled profits since it was acquired in 2021, benefiting from a commercial transformation program that improved margins without impacting customer service. Satchell also noted the sale of Lorien Engineering, aligning with the company's focus on learning and talent development. This strategy, alongside prudent financial management, positioned the company well in the tough economic climate. For 2024, the company anticipates revenues similar to 2023, with continued emphasis on acquisitions and leveraging AI in learning tools to enhance operational efficiency and data insights. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:31 AM Eastern Daylight Time

Video
1 ... 34567 ... 3443